Literature DB >> 29844146

Activin A and Late Postpartum Cardiac Dysfunction Among Women With Hypertensive Disorders of Pregnancy.

Sajid Shahul1, Hadi Ramadan2, Junaid Nizamuddin3, Ariel Mueller2, Vijal Patel3, John Dreixler3, Avery Tung3, Roberto M Lang4, Lynn Weinert4, Rabab Nasim2, Sireesha Chinthala2, Sarosh Rana2.   

Abstract

Women with hypertensive disorders of pregnancy have an increased risk of subsequent heart failure and cardiovascular disease when compared with women with normotensive pregnancies. Although the mechanisms underlying these findings are unclear, elevated levels of the biomarker activin A are associated with myocardial dysfunction and may have predictive value. We hypothesized that elevated levels of antepartum activin A levels would correlate with postpartum cardiac dysfunction in women with hypertensive disorders of pregnancy. We prospectively studied 85 women to determine whether increased antepartum activin A levels were associated with cardiac dysfunction at 1 year postpartum as measured by global longitudinal strain. Thirty-two patients were diagnosed with preeclampsia, 28 were diagnosed with gestational or chronic hypertension, and the remainder were nonhypertensive controls. Activin A levels were measured with ELISA both in the third antepartum trimester and at 1 year postpartum. Comprehensive echocardiograms including measurement of global longitudinal strain were also performed at enrollment and at 1 year postpartum. Antepartum activin A levels correlated with worsening antepartum global longitudinal strain (r=0.70; P=0.0001). Across the entire cohort, elevated antepartum activin A levels were associated with the development of abnormal global longitudinal strain at 1 year (C statistic 0.74; P=0.004). This association remained significant after multivariable adjustment for clinically relevant confounders (C statistic 0.93; P=0.01). Postpartum activin A levels also correlated with increasing left ventricular mass index (P=0.02), increasing mean arterial pressures (P=0.02), and decreasing E' values (P=0.01). Activin A may be a useful tool for identifying and monitoring patients at risk for postpartum development of cardiovascular disease.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  activin; cardiovascular disease; echocardiography; preeclampsia; pregnancy

Mesh:

Substances:

Year:  2018        PMID: 29844146     DOI: 10.1161/HYPERTENSIONAHA.118.10888

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Persistent cardiac dysfunction on echocardiography in African American women with severe preeclampsia.

Authors:  Lisa D Levine; Jennifer Lewey; Nathanael Koelper; Katheryne L Downes; Zolt Arany; Michal A Elovitz; Mary D Sammel; Bonnie Ky
Journal:  Pregnancy Hypertens       Date:  2019-05-30       Impact factor: 2.899

2.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

Review 3.  Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: Recent Advances in Hypertension.

Authors:  Kavia Khosla; Sarah Heimberger; Kristin M Nieman; Avery Tung; Sajid Shahul; Anne Cathrine Staff; Sarosh Rana
Journal:  Hypertension       Date:  2021-08-15       Impact factor: 10.190

Review 4.  The Use of Echocardiography and Advanced Cardiac Ultrasonography During Pregnancy.

Authors:  Anna C O'Kelly; Garima Sharma; Arthur Jason Vaught; Sammy Zakaria
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-21

5.  Activin type II receptor signaling in cardiac aging and heart failure.

Authors:  Jason D Roh; Ryan Hobson; Vinita Chaudhari; Pablo Quintero; Ashish Yeri; Mark Benson; Chunyang Xiao; Daniel Zlotoff; Vassilios Bezzerides; Nicholas Houstis; Colin Platt; Federico Damilano; Brian R Lindman; Sammy Elmariah; Michael Biersmith; Se-Jin Lee; Christine E Seidman; Jonathan G Seidman; Robert E Gerszten; Estelle Lach-Trifilieff; David J Glass; Anthony Rosenzweig
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

6.  Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat.

Authors:  Laura E Coats; Bhavisha A Bakrania; Daniel R Bamrick-Fernandez; Allison M Ariatti; Adam Z Rawls; Norma B Ojeda; Barbara T Alexander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-19       Impact factor: 4.733

7.  Soluble Flt1 levels are associated with cardiac dysfunction in Black women with and without severe preeclampsia.

Authors:  Lisa Levine; Zolt Arany; Adina Kern-Goldberger; Nathanael Koelper; Jennifer Lewey; Mary D Sammel; Michal A Elovitz; Bonnie Ky
Journal:  Hypertens Pregnancy       Date:  2020-12-20       Impact factor: 2.108

8.  The Reduced Uterine Perfusion Pressure (RUPP) rat model of preeclampsia exhibits impaired systolic function and global longitudinal strain during pregnancy.

Authors:  Bhavisha A Bakrania; Michael E Hall; Sajid Shahul; Joey P Granger
Journal:  Pregnancy Hypertens       Date:  2019-10-24       Impact factor: 2.899

9.  Incidence of essential hypertension but not echocardiographic abnormalities at four years with a history of preeclampsia with severe features.

Authors:  Arthur Jason Vaught; Anum Minhas; Theresa Boyer; Alexia Debrosse; Garima Sharma; Dhananjay Vaidya; Pamela Ouyang; Sammy Zakaria; Monica Mukherjee
Journal:  Pregnancy Hypertens       Date:  2021-06-12       Impact factor: 2.899

10.  Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia.

Authors:  Victoria A deMartelly; John Dreixler; Avery Tung; Ariel Mueller; Sarah Heimberger; Abid A Fazal; Heba Naseem; Roberto Lang; Eric Kruse; Megan Yamat; Joey P Granger; Bhavisha A Bakrania; Javier Rodriguez-Kovacs; Sarosh Rana; Sajid Shahul
Journal:  J Am Heart Assoc       Date:  2021-02-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.